To date, no randomized clinical trial on the comparison between simultaneous and sequential bilateral cochlear implants (BiCIs) has been performed.
V arious observational studies have shown that individuals who receive bilateral cochlear implants (BiCIs) are better able to localize sounds and perceive speech in noise than are patients who receive a unilateral implant. [1] [2] [3] [4] These findings were recently confirmed in a randomized clinical trial (RCT) on the effectiveness of simultaneous BiCIs compared with a unilateral cochlear implant, which showed that participants who received BiCIs benefit in difficult listening situations when speech and noise are spatially separated and in various localization tests. 5 The results remained stable for at least 2 years of follow-up. 6 Although the rate of deaf adults receiving BiCIs is increasing, the question remains whether simultaneous BiCIs lead to better hearing results than do sequential BiCIs. Systematic reviews suggest that simultaneous BiCIs may result in better postoperative outcomes than sequential BiCIs in children and that a prolonged interval between implants may have a negative effect or, at best, no effect on postoperative outcomes in children. 7, 8 Comparative studies on simultaneous vs sequential BiCIs in adults have not been conducted, to our knowledge. The best available evidence to date are the previously mentioned observational studies that show that both simultaneous and sequential BiCIs result in better postoperative outcomes compared with a unilateral cochlear implant. [1] [2] [3] [4] [5] The outcomes of the studies are, however, difficult to compare since a great deal of heterogeneity exists between the studies regarding study design, sample size, follow-up duration, and outcome measures.
The primary aim of this study was to compare the results of simultaneous BiCIs with those of sequential BiCIs with a 2-year interval between implants in adults with severe to profound postlingual sensorineural hearing loss. The secondary aim was to evaluate the results of 3 consecutive years of follow-up for the sequential and the simultaneous BiCI groups separately.
Methods

Ethical Considerations
The study was approved by the Human Ethics Committees of all participating centers (University Medical Center [UMC] Utrecht, Maastricht UMC, Radboud UMC, Leiden UMC, and UMC Groningen) (NL2466001808), was registered in the Dutch Trial Register (NTR1722), and conducted according to the Declaration of Helsinki. 9 Written informed consent was obtained from all participants.
Study Design
We conducted a multicenter RCT to compare the hearing results after receiving simultaneous BiCIs with the hearing results after receiving sequential BiCIs in adults with severe to profound bilateral postlingual sensorineural hearing loss. The full protocol is in Supplement 1. We reported data according to the CONSORT statement.
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Between January 12, 2010, and September 2, 2012, all participants eligible to participate in this study were discussed, and inclusion and exclusion criteria for each participant were verified. 5 The inclusion criteria were as follows: (1) age of 18 to 70 years; (2) postlingual onset of sensorineural hearing loss; (3) pure-tone average hearing loss of 70 dB or higher in each ear; (4) duration of severe to profound heraing loss of less than 20 years in each ear and a difference in duration of deafness between the 2 ears of 10 years or less; (5) ability to hear with or without hearing aid until 10 years or less; (6) marginal hearing aid benefit, defined as an aided phoneme score of 50% or less at a 65-dB sound pressure level; (7) Dutch as native language; (8) willingness and ability to participate in all scheduled procedures; (9) general health allowing general anesthesia for the duration of potential simultaneous BCIs; (10) Dutch health insurance coverage; and (11) agreement to be implanted with Advanced Bionics implants. The exclusion criteria were as follows: (1) previous cochlear implant; (2) abnormal cochlear anatomy; and (3) chronic ear infections. After providing informed consent, undergoing hearing evaluations, and providing self-reported questionnaires on hearing and quality of life (QoL), participants were randomly allocated to 1 of 2 treatment groups. Using a web-based randomization program, participants were randomized to either simultaneous BiCIs or sequential BiCIs with an interval of 2 years between implants. We used a block randomization per center strategy to obtain an equal distribution between sequential and simultaneous BiCI groups in all centers.
Intervention
All participants were implanted with HiRes90K implants (Advanced Bionics) and used Harmony processors (Advanced Bionics) with high resolution or high resolution 120 processing strategies. Implantation and rehabilitation (≥6 weeks) were performed in the participants' own hospitals, and rehabilitation decisions were based on the surgeon's and audiologist's expertise.
Hearing Evaluation
Hearing tests were conducted using the AB-York Crescent of Sound. 5, 11 All tests were performed with BiCIs, except for participants in the sequential BiCI group prior to receiving their second cochlear implant. For these participants, we defined the participant's preferred situation as the maximum score reached either with cochlear implant only or cochlear implant plus hearing aid. When comparing follow-up years, we compared the results after receiving sequential BiCIs with the participant's preferred situation.
Primary and Secondary Outcomes
The primary outcome was speech intelligibility in noise from straight ahead, measured with the Utrecht-Sentence Test with Adaptive Randomized Roving levels, 12 which resulted in a speech reception threshold in noise. A speech reception threshold in noise of 30 dB was considered relative silence and was used as a cutoff if participants scored 30 dB or higher on all speech-in-noise tests. Speech intelligibility in noise from spatially separated sources (SISSS) was an objective secondary outcome. Sentences were presented from 60°to the left (-60°azimuth) or to the right (+60°a zimuth) of the participant, and the noise was presented from the opposite side. 13 When sounds come from different directions, participants usually have a best performing situation and a worst performing situation. A participant's best performing situation was defined when speech was presented to the ear with the lowest signal to noise ratio (SNR) and noise to the ear with the highest SNR.
In participants' worst performing situations, speech and noise originated from the opposite sides. In the sequential BiCI group, before the implantation of the second cochlear implant, the best performing situation was defined as the situation in which the sound was presented to the implanted ear and the noise to the nonimplanted ear. After BiCIs, the ear with the lowest SNR was defined as the best performing cochlear implant's side. Another objective secondary outcome was maximum speech intelligibility in silence, measured with the Dutch consonant vowel consonant test at varying decibel sound pressure levels. A third objective secondary outcome was localization capabilities in a setup with horizontally placed loudspeakers in an arc around the participant. Numbers were shown on screens, representing the loudspeaker above them. Thirty phrases were presented randomly at 60-, 65-, or 70-dB sound pressure level from one of the loudspeakers. Participants were instructed to face the loudspeaker in front during the procedure. The results were the percentage of correct responses in the following 3 localization conditions: 15°angle azimuth between loudspeakers (-30°, -15°, 0°, 15°, and 30°); 30°angle azimuth between loudspeakers (-60°, -30°, 0°, 30°, and 60°); and 60°angle azimuth between loudspeakers (-60°, 0°, and 60°). Subjective secondary outcomes were self-reported benefits assessed with different quality of hearing questionnaires. The first was the Speech, Spatial and Qualities Hearing Scale (SSQ), which consists of 3 domains: speech (SSQ1), spatial hearing (SSQ2), and quality of hearing (SSQ3).
14 The second was the Nijmegen Cochlear Implant Questionnaire (NCIQ), which assesses 6 subdomains of hearing, 15 
Statistical Analysis
Statistical analysis was conducted from May 24 to June 12, 2016. Before analysis, all data were double-checked by 2 independent individuals. Most of the data were not normally distributed. We thus calculated median values and interquartile ranges. We used the Mann-Whitney test to compare the 1-year results from the simultaneous BiCI group with the 3-year results from the sequential BiCI group (1 year after sequential BiCIs). All analyses were 2-tailed, and a P < .05 was considered statistically significant. We used the Wilcoxon signed rank test to compare the 3-year results with the 1-year and 2-year results for the simultaneous and sequential BiCI groups separately, and we used Bonferroni correction for multiple testing. Median difference data were reported, including a 95% CI derived from the Hodges-Lehmann estimate in SPSS, version 22 (SPSS Inc).
Missing Data
In case of loss to follow-up in either group, we performed a per protocol (PP) analysis and a last observation carried forward (LOCF) analysis in which missing data were replaced by the participant's last results before dropout. This analysis meant that unilateral scores were used for the sequential BiCI results after 3 years of follow-up in participants unavailable for follow-up.
Results
Participant Characteristics
A total of 19 participants were included in each group. Baseline characteristics are described in Table 1 . Hearing aid use before implantation was imbalanced between groups (sequential BiCI group, 19 participants; simultaneous BiCI group, 15 participants). Linear regression analysis revealed no confounding role of hearing aid use (t 36 = 0.05; P = .96).
Loss to Follow-up and Missing Data
After providing written informed consent, 1 participant in each group withdrew and was replaced by new participants. One of the participants who withdrew had received a diagnosis of Kahler disease, and 1 preferred to be implanted with another brand of cochlear implant. During the second and third year, 2 participants in the sequential BiCI group withdrew because of personal reasons. Another participant was excluded from the sequential BiCI group because of poor results with the first implant and low expectations after sequential BiCIs owing to central deafness caused by rhesus antagonism (Figure 1) . At 1 year after implantation, the 15°localization results were missing for 1 participant in the simultaneous BiCI group. At 3 years after implantation, the Time Trade-off result was missing for 1 participant in the sequential BiCI group, and the VAS on health and hearing was missing for another participant in the sequential BiCI group. A cutoff of 30 dB was used for the speech reception threshold for 1 participant in each group.
Simultaneous vs Sequential BiCIs Objective Results
As shown in the PP data in Table 2 and Figure 2 , no significant differences were seen between the 1-year results in the simultaneous BiCI group and the 3-year results in the sequential BiCI group for all objective outcomes except for the 30°localiza-tion task. In the PP and LOCF analyses, the participants in the simultaneous BiCI group performed significantly better than those in the sequential BiCI group (PP: difference, -10% [95% CI, -20.1% to 0%]; LOCF: difference, -13.3% [95% CI, -23.3% to -3.3%]).
Subjective Results
As shown in the PP data in Table 2 , Figure 3 , and the eFigure in Supplement 2, no significant differences were seen in the PP and the LOCF analyses on all subjective results between both groups. The score for the simultaneous BiCI group, although higher on all questionnaires except for 2 subdomains of the NCIQ, were not significantly different from the sequential group scores.
Sequential BiCIs: Comparing Follow-up Years
Objective Results As shown in Figure 2 , participants in the sequential BiCI group performed better 1 year after receiving their second cochlear implant compared with previous years. A significant benefit was seen on the SISSS in the worst performing situation (difference between year 1 and year 3, -6.8 dB [97.5% CI, were also not significant after correction for multiple testing.
As shown in the eFigure in Supplement 2, no significant differences were seen on the results of the QoL questionnaires in the sequential BiCI group. Results of original data and LOCF data did not differ.
Simultaneous BiCIs: Comparing Follow-up Years
When we compared the 3-year follow-up data with the 1-year and 2-year data for the participants in the simultaneous BiCI group, a significant improvement of -2.50 dB (97.5% CI, -4.85 to -0.01 dB) was seen for the best performing situation on the SISSS between year 1 and year 3. After correcting for multiple testing, we found that a 6.7% increase (97.5% CI, -0.01% to 15.0%) in performance on the 15°localization task between year 2 and year 3 was not significant. No differences were observed for any of the other objective and subjective outcomes (Figures 2 and 3 ; eFigure in Supplement 2).
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Discussion
In this study, we present the results of the first RCT, to our knowledge, comparing simultaneous and sequential BiCIs in postlingually deafened adults. In addition, we present the 3-year follow-up results for both study groups separately. First, the simultaneous BiCI group and the sequential BiCI group performed equally 1 year after receiving BiCIs on all objective and subjective hearing tests, except for the 30°l ocalization task. The sequential BiCI group did not need a longer follow-up to reach the same level of speech perception as the simultaneous BiCI group. So far, studies have solely examined the benefit of BiCIs vs a unilateral cochlear implant, but a comparison between sequential and simultaneous BiCIs has not yet been attempted. 1, 2, 4 Because it requires auditory stimulation during early ages to achieve effective central auditory development, a critical period exists for pediatric cochlear implantation. Given this critical period, simultaneous BiCIs have advantages over sequential BiCIs in children. 20 Simultaneous BiCIs guarantee the implantation of the better ear and the earlier implantation of the second ear, which may facilitate the development of binaural hearing. In postlingually deafened adults, the auditory system is fully developed, which may explain the similar results between our 2 study groups. Second, we found that the participants in the sequential BiCI group benefit from BiCIs in the same listening situations as do the participants in the simultaneous BiCI group: difficult listening situations with speech and noise from spatially separated sources in participants' worst performing situation and on several localization tasks. These findings were confirmed by improved scores on questionnaires concerning perception of speech, spatial hearing, and quality of hearing (SSQ) and the social interaction subdomain on the NCIQ.
Two study participants dropped out of the sequential BiCI group for personal reasons. Both participants were satisfied with the results that they obtained with their first cochlear implant, which is in accordance with the significant improvement in QoL found in this study 1 year after a unilateral cochlear implant. However, sequential BiCIs could further improve these participants' spatial hearing capabilities (hearing in noise from spatially separated sources and localization), as shown in this study.
Five earlier studies [21] [22] [23] [24] [25] Correct, % -4.69 to -0.32 dB] ). This improvement may result from binaural integration, as measured through one of the binaural hearing effects: the squelch effect.
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Strengths and Limitations
To our knowledge, this is the first RCT examining the effect of simultaneous vs sequential BiCIs on various hearing outcomes. The use of this design minimized allocation bias. In addition, the study population was homogenous; for example, onset of hearing loss was not allowed to differ more than 10 years between ears. A longer interval between ears might have caused an unfavorable result in the sequential BiCI group owing to sound deprivation of the longerdeprived ear. 27 Three participants were unavailable for follow-up in the sequential BiCI group. We performed both a PP analysis and an LOCF analysis and found that this loss had no influence on the results. Owing to the multicenter nature of this study, implantation procedures may vary between centers. In addition, the sample size calculation incorporated loss to follow-up; therefore, the study had sufficient power to detect a difference on the primary outcome measure. However, the sample size might have been too small for secondary outcomes such as QoL questionnaires because smaller subjective changes were expected between the 2 groups. In addition, these questionnaires were unable to detect changes in QoL after cochlear implantation because they do not incorporate a specific hearing element. On 2 of these questionnaires (Time Trade-off, EuroQol 5-Dimension), ceiling effects were noted that hindered differentiation between study groups. Finally, this study focused solely on subjective and objective speech perception outcomes and did not incorporate other factors that affect the choice for simultaneous vs sequential BiCIs, such as cost utility and surgical complications (such as bilateral areflexia). 28 We plan to study the differences between the first and second ear implanted in the sequential BiCI group and to investigate whether these participants demonstrate a clinically relevant binaural squelch effect.
Conclusions
In this RCT, we compared the objective and subjective results of simultaneous BiCIs and sequential BiCIs in adults with severeto-profound hearing loss. This study demonstrates that individuals who receive sequential BiCIs derive the same benefit as those who receive simultaneous BiCIs on speech perception 1 year after receiving their second cochlear implant. Participants who underwent sequential BiCIs had significant improvements in spatial speech-in-noise and localization abilities compared with their unilateral situation before receiving a second cochlear implant. These findings were consistent with the participants' self-reported hearing capabilities. Three years after simultaneous BiCIs, the spatial speech-in-noise abilities of the participants increased for the best performing situation. All other objective and self-reported hearing capabilities remained stable. These findings suggest that simultaneous BiCIs offer long-term stable results in adults with severe-to-profound bilateral sensorineural hearing loss. Role of the Funder/Sponsor: The funding source collaborated with the authors on the study design. They had no influence on the conduct of the study, data collection, management, data analysis or data interpretation. The funding source did not review or approve the content of the manuscript before submission. The funding source did not, by research agreement contract, have the ability to change the content of the manuscript or withhold publication of any of the data. Objective: The objectives are to evaluate the degree of bilateral benefit gained from having a second implant and to determine whether this benefit is stronger after simultaneous or sequential implantation.
Study design: 48 subjects with severe sensorineural hearing loss will be included in this Randomised Controlled Trial. 28 Subjects shall receive one implant at the beginning of the study and a second implant after a period of two years (Group A). 20 Subjects shall receive two cochlear implants simultaneously during one operation (Group B). The quality of life results of the subjects included in this study will be compared to the results of a control group of 20 additional un-randomised patients who will receive a unilateral CI via regular medical treatment.
Study population: 48 subjects with an age between 18 and 70 years with severe sensorineural hearing loss who are eligible for cochlear implantation.
Intervention (if applicable):
Bilateral Cochlear Implantation.
Main study parameters/endpoints:
The main outcome will be the performance on the Nature and extent of the burden and risks associated with participation, benefit and group relatedness: For group A subjects: the risks of the second surgery are considered equal to the risks of the first surgery. When worsening of the health status of a subject no longer allows a second surgery, the subject will be excluded from further implantation. For group B subjects: the duration of surgery will be prolonged with approximately 50% of the standard operation time. The evaluation consists of 5 test sessions of 4 hours each, spread over four years time.
INTRODUCTION AND RATIONALE
Introduction
The present study was initiated by Prof. Dr. W. Grolman (University Medical Centre Utrecht) who approached Mr. P. Boyle (Clinical Research Department, Advanced Bionics) at the beginning of 2007 for a research collaboration on adult bilateral cochlear implantation with the idea of using a randomised controlled trial to compare simultaneous and sequential bilateral implantation. After thorough discussion and with the precious participation of Prof.
Q. Summerfield (Department of Psychology, University of York), the following protocol was established.
The HiResolution Bionic Ear is an implantable prosthesis designed to provide individuals with severe or profound hearing loss, who obtain limited benefit from conventional hearing aids, access to sound and improved perception of speech via electrical stimulation of the auditory nerve. Many users of one Bionic Ear achieve high levels of spoken word recognition when speech is presented in quiet. However, even the most successful users experience difficulty in the presence of competing sounds and are poor at identifying where sounds come from. These limitations may be overcome, to some degree, by providing an implant to both ears. This study will investigate bilateral versus unilateral benefit in adults who are implanted with two Bionic Ears either simultaneously or sequentially. The objectives are to evaluate the degree of bilateral benefit gained from having a second implant and to determine whether this benefit is stronger after simultaneous or sequential implantation.
Participants will be using HiRes or HiRes Fidelity 120 (also called HiRes 120) sound processing according to their preference, with the restriction of using the same sound processing strategy on both sides. This approach may give insights into the benefits observed with HiRes in comparison to those observed with HiRes 120 via a separate analysis.
This study will be conducted as a randomised controlled trial (RCT) to control for biases when assigning subjects to one of two study groups. RCTs are the most rigorous experimental design for establishing the effectiveness of one intervention compared with another (Woolf et al., 1990) . However, the study is considered a non-significant risk evaluation of a treatment which is commonly clinically applied (unilateral cochlear implantation) with one which is increasingly commonly applied clinically in children (bilateral cochlear implantation) in numbers of European countries. The failure of bilateral implantation to also be applied to adults is largely financial; there being no compelling evidence of sufficiently large benefits of bilateral over unilateral implantation to justify the additional cost.
All products in the study (i.e., HiResolution Bionic Ear System, SoundWave programming software) have been approved for commercial distribution within the European Community.
Previous research indicates that there are no significant additional safety issues when patients receive two devices instead of just one, even if performed in the same surgery.
Efficacy with two devices appears to be greater than with one implant although, as stated above, the quality of study conducted to date leaves room for refusal to accept study findings through a failure to control various forms of bias. The poor standard of studies on bilateral cochlear implantation has been recently highlighted by Murphy and O'Donoghue (2007) .
Rationale
Normal-hearing listeners gain important everyday benefits from having two ears. One advantage is the ability to determine where sounds are coming from (e.g., Middlebrooks and Green, 1991) . The other important advantage is the ability to hear sounds and understand speech in noisy environments, especially if the sound sources come from different directions (e.g., Bronkhorst and Plomp, 1988; Dirks and Wilson, 1969; MacKeith and Coles, 1971 ).
More specifically, normal listeners have the following capabilities.
Localisation.
Normal listeners are able to localise sound in the horizontal plane (at ear level)
with an accuracy of +/-14 degrees (Stevens and Newman, 1936) . The brain uses interaural differences in intensity and time between the two ears to determine the location of a sound source in the horizontal plane (Akeroyd, 2006) . To localise sound in the vertical plane, or when interaural time and intensity cues are ambiguous, spectral information is important. The external ear alters the relative intensities of the many frequencies entering the ear canal. The direct path to the tympanic membrane and the delayed path caused by reflection of sound around the pinna and off the concha add together to produce a filtered spectrum containing a characteristic pattern of peaks and valleys across frequencies. The amplitude spectrum of a complex sound reaching the tympanic membrane differs depending upon the location of the sound relative to the body (see Middlebrooks et al., 1989) .
Head shadow.
When listening to speech in noise, the head acts as a sound barrier that attenuates noise on the side contralateral to the signal. Therefore, when one ear is closer to the noise source, adding a second ear contralateral to the noise provides an ear with a better signal-to-noise ratio (SNR). The head shadow effect is purely geometric and does not require binaural processing by the brain.
Binaural squelch.
When signals and noise come from different directions, the brain is able to separate them by comparing time, intensity, and spectral differences between the two ears. The practical effect is that the brain is able to suppress signals that the listener does not wish to hear.
Binaural summation.
When identical signals are presented to the two ears, there is an advantage when hearing with both ears instead of just one alone. The brain uses binaural redundancy and binaural loudness summation to produce this advantage.
Based upon the advantages normal-hearing listeners derive from hearing with two ears, several research centres have studied the benefits of bilateral cochlear implantation with the Nucleus and MED-EL devices (e.g., Gantz et al., 2002; Litovksy et al., 2004; Müller et al., 2002; Nopp et al., 2004; Schleich et al., 2004; Tyler et al., 2002) . Taken together, these studies indicate that most, if not all, bilateral implantees experience near-normal head shadow effects. They are also able to localise sound with two implants significantly better than with one implant alone. Fewer bilateral implant users exhibit binaural summation and binaural squelch effects. Notably, there have been no reports of decrements in speech perception or localisation for bilateral vs. unilateral implant use. Moreover, in cases where preference was assessed, all patients strongly preferred two implants to using one implant with the better ear alone.
A recent review (Murphy & O'Donoghue, 2007) highlighted the lack of high quality studies of bilateral implantation which would be capable of controlling for bias and hence accepted by commissioners of healthcare. Such findings demonstrate the need for studies capable of quantifying the benefits of bilateral implantation in both clinical and health-economic frameworks.
Another important aspect which concerns the benefits provided by bilateral implantation is the need for fine frequency information; it is of indisputable importance to convey fine structure, particularly for speech recognition in noise and for melody recognition (Wilson et al., 2005) . Previously, the University of Iowa has reported bilateral results from four subjects who were implanted simultaneously with two Bionic Ears and were initially programmed with the Continuous Interleaved Sampler (CIS) conventional strategy (Tyler et al., 2004 because there is no spatial separation of signal and noise. The results showed substantial improvement in performance with HiRes after only one month of use. Notably, the improvement in sentence-in-noise scores after switching to HiRes was much greater for users of two Bionic Ears than the mean improvement in scores for subjects using only one Bionic Ear (Koch et al., 2004) . Within this study, the term HiRes processing shall include HiRes Fidelity® 120 processing, the more individually beneficial processing approach between "standard" HiRes and HiRes 120 being applied to any particular subject.
OBJECTIVES
Based upon the fact that users of two implants demonstrate quantifiable improved benefit over single-implant use, upon the need for studies in which the methodology strongly controls for biases such as in RCTs, and upon preliminary data indicating that HiRes sound processing may provide enhanced binaural benefit, this study will:
(1) Evaluate the efficacy of bilateral implant use with HiRes after simultaneous implantation compared to a unilateral control group in a between-subjects design;
(2) Compare the benefits of HiRes applied unilaterally to bilateral use after sequential implantation using a within-subject design;
(3) Compare the efficacy of HiRes from simultaneous bilateral implantation with sequential bilateral implantation where there is a two-year gap between implantations using a between-subject design.
The results should document the benefits of using two implants versus one. We would like to determine whether simultaneous bilateral implantation holds any advantages over a modest delay in implanting the second ear. The study will also document the duration of each operation, medical or surgical complications, as well as any adverse events associated with bilateral implantation. Given that this is an RCT, various forms of selection bias will be avoided. Since all subjects ultimately receive bilateral implantation, there shall be no withholding of treatment; addressing an important ethical dimension to this work.
STUDY DESIGN
Subject selection shall take account of differences in hearing thresholds between ears, duration of deafness, anatomical and aetiological issues as well as psychological and motivational attributes. Subjects assigned to simultaneous bilateral implantation shall receive two implants at the beginning of the study and be evaluated before surgery and after one, two, three and four years of bilateral implant use (Group B). The group assigned to sequential implantation shall receive one implant at the beginning of the study and be evaluated before this first surgery and one and two years thereafter. After two years they shall receive a second implant. Evaluation will take place after one and two years of bilateral use (Group A).
Those subjects randomised for simultaneous implantation will be implanted with two Bionic
Ears at the same surgery (or within one month of each other, should medical opinion require a delay). The devices will be programmed at the same time 4-6 weeks after surgery (or after the second surgery). The same processing strategy (HiRes or HiRes 120), shall be applied to both implants and parameters shall be controlled to minimise differences between ears.
Subjects randomised for sequential implantation shall receive the first Bionic Ear implant in one ear to be chosen according to the following guidelines: for subjects wearing a hearing aid, the ear without hearing aid will be the first ear to be implanted; for subjects wearing two or no hearing aids, an attempt to randomise between the "better" or "worse" ear will be carried out. Since the goal of the study is to compare bilateral cochlear implantation with the next best alternative, the use of a contralateral hearing aid shall be encouraged for the unilateral users.
Forty subjects will each be assigned to one of the two study groups described above. A sample size of 20 subjects in each group is required to allow valid statistical assessment of bilateral benefit (see power calculations). In order to compensate for potential subject attrition, a total of 48 subjects will be recruited. The additional eight subjects shall be "randomised" to sequential implantation since it is from this group that attrition is anticipated with failure to take up their second implant after the initial "unilateral" phase.
Subjects shall be randomised into one of the two groups using a strict randomisation process. Subjects willing to participate must be informed that they can be assigned to either condition or accept to submit to this randomisation. It is only after the subject has signed their consent form that he/she is informed of the assigned group.
A further concern regarding the sequential group is that the knowledge that a subject is going to receive a second implant might change, or bias, their judgment of their quality-of-life.
Accordingly, a third group will be recruited (un-randomised) to control for this. Following the recruitment of the initial 48 subjects, the next 20 subjects who fit within the inclusion criteria will be recruited into this third group. The members of this un-randomised group will not receive a second implant. They will complete the same self-report measures of quality-of-life as other subjects before surgery and after one and two years of unilateral implant use since those are the time points at which the sequential group would complete assessments as unilateral users before receiving their second implant. The third arm's auditory skills and speech understanding will not be tested during the study since only the expectations on quality of life need to be controlled.
STUDY POPULATION
Population (base)
Subjects eligible for participation in the study must be adults who will be implanted bilaterally, either immediately or after a two year period of unilateral implantation, with two HiResolution Bionic Ears (HiRes 90K implants).
Inclusion criteriaAge ≥ 18 and ≤ 70 years.
1. Postlingual onset of hearing loss, defined as: the patient did not attend education for hearing impaired, but went to a regular primary school.
2. Sensory hearing loss of a severe or greater degree in both ears, defined as pure tone average (500, 1000, 2000 Hz) > 70 dB HL.
3. A comparable duration of severe-to-profound hearing loss between the two ears (difference between the ears: <10years).
4. Subject was able to use hearing aids until at least 10 years ago.
5. Marginal hearing aid benefit with hearing aids, defined as an aided phoneme score < 50% at 65 dB SPL in patients with onset of hearing loss in adulthood.
6. Dutch language proficiency.
7. Willingness and ability to participate in all scheduled procedures outlined in the protocol.
8. General health allowing general anaesthesia for the potential implantation of two cochlear implants during a single surgery.
9. Patients covered by the Dutch health insurance.
10. Patients should agree to be implanted with cochlear implants from Advanced Bionics.
Exclusion criteria
1. Previous implant experience.
2.
Disability which could interfere with the completion of the tests.
3.
Abnormal cochlear anatomy in one or both ears.
4.
Chronic ear infection in one or both ears.
Sample size calculation
To detect a clinically relevant difference of 5 dB SNR (SD 5 dB) between the groups on the Hearing in Noise test (modified Plomp test), with an alpha of 0.05 and a power of 80%, 16 subjects per group are needed.
In order to compensate for any data lost through drop out of subjects during the study or failure to perform a required test within the limits of the protocol 4 extra subjects will be added to the 16 subjects needed in each group. Thus, adequate statistical power will be achieved with 20 patients per group, i.e. 40 in total. An additional modest increase of eight subjects in the "sequential implantation" group is proposed, since it is from this group that attrition is anticipated with failure to take up their second implant after the initial unilateral phase. Leaving a total randomised study population of 48 subjects.
TREATMENT OF SUBJECTS
Investigational product/treatment
Preoperative medical evaluation will be carried out locally by the centre's Cochlear Implant Team, the anaesthesiologist and the patient's ENT surgeon and includes a clinical history and interview, determination of general health status and suitability for surgery, an otologic examination and radiographic evaluation of each ear, preferably using CT scans. Routine audiological testing will be performed to determine the degree and type of hearing loss. Clinical routine speech recognition testing will be performed to establish candidacy.
Before (the first) surgery, subjects will be asked to read and sign the Information and Consent Form presented by the patient's ENT surgeon. This physician will fill in a Demographics Form to gather subject information such as the date of birth and audiological information.
Baseline evaluation for gathering study-related data will take place locally, before (the first) surgery:
1. Pure tone audiometry 2. Speech audiometry with use of the most appropriate hearing aids (CVC score in quiet)
3. Questionnaires: SSQ, HUI3, NCIQ, TTO, VAS, EuroQol-5D and Tinnitis questionnaires.
The standard surgical procedures developed for placement of the internal components of the HiRes 90K will be followed. It is anticipated that most of the bilateral implants for the group with simultaneous implantation will be placed during the same surgery. Specific procedures for implanting the two devices will be left to the discretion of the surgeon.
The patients will be asked to fill in a weekly costs diary starting on the day of (the first) surgery until the end of the study. The participants are only required to fill in the diary if they have physical complaints regarding the CI or if they generate costs.
The first follow-up visit will occur approximately four to six weeks after surgery (or the second delayed surgery of a "simultaneous" bilateral implantation) to custom fit the processor(s) using the SoundWave Professional Suite software. Routine clinical procedures will be used to fit either the HiRes or HiRes 120 sound processing algorithm according to subject preference, whenever possible to determine. All subjects will be fitted with the Harmony® sound processor. For the simultaneously implanted group, both devices will be fitted on the same day, even if the devices were placed in separate operations. The two processors will be fitted independently and sequentially during the same fitting session.
An electronic copy of the SoundWave program for each ear will be submitted to Advanced Bionics .
Post-implantation evaluation sessions for collecting data will take place at one, two, three and four years after first fitting. For the sequential subjects who will be receiving their second implant after two years of unilateral use, two session will occur one and two years after the first fitting, the last two sessions will occur one and two years after the second fitting (i.e. one and two years after bilateral use). All objective evaluation measurements will take place at the UMC Utrecht to ensure that the data are gathered in an identical way.
If considered necessary, extra sessions can exceptionally be added, during which subjects will do no more than what they would do at the regular sessions.
Use of co-intervention (if applicable)
Since the goal of the study is to compare bilateral cochlear implantation with the next best alternative, the use of a contralateral hearing aid shall be encouraged for the unilateral users. 
Secondary study parameters/endpoints (if applicable)
Objective: 
Randomisation, blinding and treatment allocation
40 subjects will each be assigned to one of the two study groups, 20 in each group. Eight additional subjects will be randomised to sequential implantation in order to compensate for potential subject attrition.
A website randomisation program shall be used to divide the subjects randomly into two groups: the sequential group (n=28) or the simultaneous group (n=20).
The randomisation chart is established before the start of the study by an independent data manager.
When a local executor recruits a subject, the physician can log on to the program and enter the subject's characteristics. A minimisation model will be used to make sure that the ratio simultaneous / sequential subjects in each hospital will be about equal (20:28 = 5:7). The physician will receive an allocation group number on his/her screen within a few seconds.
It is only after the subject has signed their consent form that he/she is informed of the assigned group.
A further concern regarding the sequential group is that the knowledge that a subject is going to receive a second implant might change, or bias, their judgment of their qualityof-life. Accordingly, a third group will be recruited (un-randomised) to control for this.
Following the recruitment of the initial 48 subjects, the next 20 subjects who fit within the inclusion criteria will be recruited into this third group. The members of this unrandomised group will not receive a second implant.
Blinding is not possible since both patients and doctors will be able to see from the outside whether a subject has one cochlear implant or two.
Study procedures
Modified Plomp test with sentences in Dutch
The Plomp sentence test is designed to determine a patient's ability to understand speech in a noisy environment. This provides a more comprehensive understanding of a person's listening capabilities in daily life than a speech intelligibility test in quiet only. The
Plomp test outcome is the critical signal-to-noise-ratio (SNR) at which 50% of sentences is understood correctly. This level is called the Speech Reception Threshold in noise (SRTn). Both sentences and noise are presented from the front at 70cm distance from the patient.
In the conventional Plomp test a response is considered correct when the presented sentence is repeated without any mistakes. A patient is tested in quiet first to check if the patient is able to perform the task. Although the Plomp test is commonly used in the clinic for patients with mild-moderate hearing loss, it has not been used routinely for cochlear implantees. A speech perception in noise test which is routinely used by a CI-team is a word perception in noise test.
The reason for this is that a number of cochlear implant users will not be able to repeat sentences 100% correctly even if presented in quiet. However, in a word test patients cannot use their language ability, as they commonly do in understanding sentences.
Therefore we have modified the scoring system of the Plomp test slightly.
In the "modified Plomp test" we will be scoring the number of words repeated back correctly instead of complete sentences. A sentence is considered to be repeated correctly when a subject repeats ≤ 2 words of the sentence incorrectly.
Test procedure:
• The sound level that corresponds to the patient's maximum CVC score in quiet (standard procedure) is the individual stimulus level that will be used for the modified Plomp test.
• The starting speech to noise level ratio (SNR) is set to +20 dB (noise 20dB less than individual sound level), at which, in most cases, less than two words per sentence should be repeated back incorrectly.
• The presentation of the noise starts 500 ms before the sentence and stops 500 ms after the sentence.
• If two or less words in a sentence are repeated back incorrectly, the SNR for the next sentence will be decreased by increasing the level of the noise, i.e., the task will be made more difficult. If more than two words are repeated back incorrectly, the SNR will be increased, i.e., the task will be made easier.
• Initially, the SNR will be changed in 10-dB steps. The step size will be reduced to 5 dB after one reversal and to 2.5 dB after the next reversal.
• This step size is used for the remainder of the sentences in the list. The average SNR used for the final ten sentences in the list is calculated and used as an estimate Self-reported benefits Self-reported benefits in everyday listening situations will be assessed with the Speech, Spatial and Qualities Hearing Scale (SSQ) (Gatehouse and Noble, 2004) .
The SSQ consists of three scales that assess different domains of hearing.
 The Speech Hearing Scale consists of 15 questions that assess the ability to separate speech from competing noise in a wide range of listening contexts.
 The Spatial Scale consists of 17 questions that assess the ability to locate sound sources and their direction of movement.
 The Sound Qualities Scale consists of 19 questions that assess naturalness and clarity of sound sources.
The subject responds to each question using a rating scale that ranges from zero (Not at all) to 10 (Perfectly).
Quality-of-life questionnaires
• The Ontario Health Utilities Index 3 is a measure of general health status. It contains questions on: vision, hearing, speech, ambulation, dexterity, cognition, emotion and pain.
• The Nijmegen Cochlear Implant Questionnaire (NCIQ) measures hearing-related quality of life and is therefore more sensitive to the differences between unilateral and bilateral implant use.
• Time Trade-off (TTO): comprises one question about how many years of the life patients are living at the moment, they would sacrifice for living with perfect hearing for the rest of their days.
• Visual Analogue Scale (VAS): comprises two 10cm scales on which patients can rate their hearing and health.
• EuroQol-5D: is a measure of general health status. It contains questions on: mobility, self-care, daily activities, pain/complaints, anxiety/depression.
Tinnitus Questionnaires
• The Tinnitus Questionnaire (TQ) encompasses 52 questions on tinnitus related to: emotional distress, cognitive distress, intrusiveness, auditory perceptual difficulties, sleep disturbance and somatic complaints.
• The Tinnitus Handicap Questionnaire (THQ) has 3 subscales: a functional subscale (11items), an emotional subscale (9items) and a catastrophic subscale (5items).
• The Utrecht Tinnitus Burden Questionnaire: This questionnaire contains questions on the severity and character of tinnitus described by subjects.
Costs diary:
• Subjects are asked to keep a weekly diary involving physical complaints and costs regarding their CI(s), starting on the day of (the first) surgery. In case they do not experience any complaints or generate costs, they do not need to fill in the diary. In case they do, we ask them to specify complaints and/or costs in the diary. All subjects will be reminded on regular basis by email to keep filling in the diary.
Withdrawal of individual subjects
Subjects can leave the study at any time for any reason if they wish to do so without any consequences. The investigator can decide to withdraw a subject from the study for urgent medical reasons.
Specific criteria for withdrawal (if applicable)
As before every surgery, the anaesthesiologist will evaluate the patient's health status. In case the health status has worsened between the first and second surgery and the anaesthesiologist advises not to continue, the patient will be excluded from further implantation.
Replacement of individual subjects after withdrawal
To anticipate on possible withdrawal 8 more subjects than needed will be recruited for group A. Therefore there will be no reason to replace subjects after withdrawal unless more subjects will withdraw than 8.
Follow-up of subjects withdrawn from treatment
During the study, each patient will stay in care of their CI-team. In case a subject is withdrawn from the study he/she will continue with the standard medical treatment provided by the CI-team.
Premature termination of the study
Serious adverse events are not expected, but in case they do occur, each member of the research group has the right to terminate the study prematurely.
SAFETY REPORTING
Section 10 WMO event
In accordance to section 10, subsection 1, of the WMO, the investigator will inform the subjects and the reviewing accredited METC if anything occurs, on the basis of which it appears that the disadvantages of participation may be significantly greater than was foreseen in the research proposal. The study will be suspended pending further review by the accredited METC, except insofar as suspension would jeopardise the subjects' health. The investigator will take care that all subjects are kept informed.
Adverse and serious adverse events
Adverse events are defined as any undesirable experience occurring to a subject during a clinical trial, whether or not considered related to the investigational drug. All adverse events reported spontaneously by the subject or observed by the investigator or his staff will be recorded.
Adverse events could be: implant failure, infection, explantation.
A serious adverse event is any untoward medical occurrence or effect that at any dose results in death;
-is life threatening (at the time of the event);
-requires hospitalisation or prolongation of existing inpatients' hospitalisation;
-results in persistent or significant disability or incapacity;
-is a congenital anomaly or birth defect;
-is a new event of the trial likely to affect the safety of the subjects, such as an unexpected outcome of an adverse reaction, lack of efficacy of an IMP used for the treatment of a life threatening disease, major safety finding from a newly completed animal study, etc.
All SAEs will be reported to the accredited METC that approved the protocol, according to the requirements of that METC.
Follow-up of adverse events
In the case of implant failure, infection, explantation or any other event resulting in the temporary non use of the implant system, subjects will not be permanently excluded from the study, under the intention to treat. Once the problem is solved, the subject will reenter and continue the study for the amount of time left since he/she had not been operational with the device. This ensures that subjects from the simultaneous group experience two years of bilateral use while those from the sequential group experience two years of unilateral use followed by two years of bilateral use within the study duration.
A separate analysis for such a subject may be further conducted to control for possible biases.
All adverse events will be followed until they have abated, or until a stable situation has been reached. Depending on the event, follow up may require additional tests or medical procedures as indicated, and/or referral to the general physician or a medical specialist.
STATISTICAL ANALYSIS
The aim of the study is to measure changes in auditory performance, speech understanding and quality of life that accompany the receipt of a second cochlear implant by subjects who receive two implants at virtually the same time, ideally simultaneously and those who have had one implant for a reasonable time period. Three types of measures will be obtained: measures of the ability to localise the source of sounds in space, measures of the ability to understand speech in a background of noise, and measures of quality of life, including both health related and non-health-related measures.
Overall, the study is an RCT, but has a repeated measures design, in which subjects who are implanted sequentially are tested with a second cochlear implant in the same manner as with one cochlear implant (or one implant and a contralateral hearing aid). Both groups will be equally tested thus providing between-group measures comparing unilateral and bilateral use as well as simultaneous and sequential bilateral benefit. The sequential group subjects will be tested again following 12 and 24 months of bilateral experience, thus providing a within subject control group for unilateral and bilateral conditions. Major test intervals are at one and two years post implantation.
First, the effect of bilateral cochlear implantation between the randomised groups will be calculated as mean differences, rate differences, and rate ratios with 95% confidence intervals. Differences in percentages and mean values between the groups will be analyzed by Chi-square tests and Student T-tests, respectively. All trial analyses will be performed on an intention-to-treat basis.
Second, each subject from the sequential group will act as his or her own control with sufficient data being collected to make within-subject comparisons. Differences in percentages and mean values before and after implantation will be calculated using paired t-tests for continuous measures and the McNemar test for percentages.
ETHICAL CONSIDERATIONS
Regulation statement
The study will be conducted according to the principles of the Declaration of Helsinki (version 2008, Seoul) and in accordance with the Medical Research Involving Human Subjects Act (WMO).
Recruitment and consent
When a patient meets the criteria for cochlear implantation and the inclusion criteria for this study, he/she will be asked to participate by a member of the Cochlear Implant team.
Like all patients eligible for cochlear implantation, the patients in this study will have several appointments with the ENT specialist, audiologist, social worker etc. There will be ample opportunity for the patient and his/her partner to consider participation and discuss their questions. The content of the study will be explained by the patient's otolaryngologist who will give the subject written patient information and the informed consent form.
Benefits and risks assessment, group relatedness
Compared to routine clinical practice, the study requires that the subjects undergo a second cochlear implantation either in an extended surgery or in an additional separate surgery. This carries the usual risks associated with surgery and a slightly longer anaesthetic exposure. The clinical management will otherwise be unaffected besides appointment times being longer to ensure that both implants are optimally working.
Efficacy with two devices seems to be greater than with one implant although the quality of studies conducted to date leaves room for refusal to accept study findings through a failure to control various forms of bias.
Compensation for injury
The sponsor/investigator has a liability insurance which is in accordance with article 7, subsection 6 of the WMO.
Incentives (if applicable)
All participants will receive compensation for travel expenses.
ADMINISTRATIVE ASPECTS AND PUBLICATION
Handling and storage of data and documents
All data will be treated confidentially. The data will be analysed anonymously by using a unique patient identification number. The key code will be safeguarded by the investigators.
The paper data files will be stored in a locked room. The data will be stored on the investigator's computer as well which is secured by a password and situated in a locked room. The subjects' general practitioner will be informed about the participation of the subject.
Amendments
Amendments are changes made to the research after a favourable opinion by the accredited METC has been given. All amendments will be notified to the METC that gave a favourable opinion.
Non-substantial amendments will not be notified to the accredited METC and the competent authority, but will be recorded and filed by the sponsor.
Annual progress report
The sponsor/investigator will submit a summary of the progress of the trial to the accredited METC once a year. Information will be provided on the date of inclusion of the first subject, numbers of subjects included and numbers of subjects that have completed the trial, serious adverse events/ serious adverse reactions, other problems, and amendments.
End of study report
The investigator will notify the accredited METC of the end of the study within a period of 8 weeks. The end of the study is defined as the last patient's last visit.
In case the study is ended prematurely, the investigator will notify the accredited METC, including the reasons for the premature termination.
Within one year after the end of the study, the investigator/sponsor will submit a final study report with the results of the study, including any publications/abstracts of the study, to the accredited METC.
eFigure. Subjective Outcomes on Health: Development Over Time for Smultaneous and Sequential BiCI
Scores of the per protocol data are presented in median values with an error bar representing the interquartile range. VAS: Visual Analogue Scale; HUI3: Health Utilities Index 3; EQ5D: Dutch EuroQol-5D; TTO: Time trade off; yr: year; CI: cochlear implant; preop: preoperative. Statistical analyses were performed between 1-year, 2-year and 3-year data, applying a Bonferroni correction. No statistical differences were found on all quality of life questionnaires between sequential and simultaneous bilateral cochlear implantation.
